|0.34 -0.009 (-2.44%)||12-05 15:59|
|Targets||6-month :||0.45||1-year :||0.53|
|Resists||First :||0.38||Second :||0.45|
|Supports||First :||0.32||Second :||0.28|
|MAs||MA(5) :||0.34||MA(20) :||0.32|
|MA(100) :||0.31||MA(250) :||0.62|
|MACD||MACD :||0||Signal :||0|
|%K %D||K(14,3) :||70.8||D(3) :||69.6|
|52-week||High :||1.46||Low :||0.22|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NRXP ] has closed below upper band by 34.5%. Bollinger Bands are 3.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||0.38 - 0.38||0.38 - 0.38|
|Low:||0.32 - 0.32||0.32 - 0.32|
|Close:||0.34 - 0.34||0.34 - 0.34|
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||85 (M)|
|Shares Float||55 (M)|
|Held by Insiders||36 (%)|
|Held by Institutions||4.2 (%)|
|Shares Short||1,540 (K)|
|Shares Short P.Month||1,900 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.08|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-109 %|
|Return on Equity (ttm)||-682.7 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-27 (M)|
|Levered Free Cash Flow||-15 (M)|
|Price to Book value||-4.25|
|Price to Sales||0|
|Price to Cash Flow||-1.08|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|